Cargando…

A Physiologically Based Pharmacokinetic Model to Predict Determinants of Variability in Epirubicin Exposure and Tissue Distribution

Background: Epirubicin is an anthracycline antineoplastic drug that is primarily used in combination therapies for the treatment of breast, gastric, lung and ovarian cancers and lymphomas. Epirubicin is administered intravenously (IV) over 3 to 5 min once every 21 days with dosing based on body surf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ansaar, Radwan, Meech, Robyn, Rowland, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143085/ https://www.ncbi.nlm.nih.gov/pubmed/37111707 http://dx.doi.org/10.3390/pharmaceutics15041222

Ejemplares similares

Tissue distribution of epirubicin after severe extravasation in humans
por: Nedomansky, Jakob, et al.
Publicado: (2021)

Combining Therapeutic Drug Monitoring and Pharmacokinetic Modelling Deconvolutes Physiological and Environmental Sources of Variability in Clozapine Exposure
por: Wills, Kenneth H., et al.
Publicado: (2021)

A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure
por: Newman, Elise M., et al.
Publicado: (2022)

Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.
por: Twelves, C. J., et al.
Publicado: (1992)

Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant
por: Yamasaki, Miho, et al.
Publicado: (2019)

Physiologically Based Pharmacokinetic Modelling to Predict Imatinib Exposures in Cancer Patients with Renal Dysfunction: A Case Study
por: Rowland Yeo, Karen, et al.
Publicado: (2023)

Use of physiological based pharmacokinetic modeling for cross-species prediction of pharmacokinetic and tissue distribution profiles of a novel niclosamide prodrug
por: Yang, Mengbi, et al.
Publicado: (2023)

Epirubicin
por: Cornish, J., et al.
Publicado: (1988)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Maternal Pharmacokinetics and Fetal Exposure to Oxcarbazepine
por: He, Lixia, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination
por: Sun, Lei, et al.
Publicado: (2020)

Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice
por: Liu, Shufang, et al.
Publicado: (2023)

Predicting Volume of Distribution in Neonates: Performance of Physiologically Based Pharmacokinetic Modelling
por: De Sutter, Pieter-Jan, et al.
Publicado: (2023)

Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body
por: Fan, Yingfang, et al.
Publicado: (2017)

Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination
por: Fenneteau, Frédérique, et al.
Publicado: (2009)

Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.
por: Scheithauer, W., et al.
Publicado: (1993)

Physiologically‐Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan
por: Sun, Lei, et al.
Publicado: (2020)

Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet
por: Sun, Lei, et al.
Publicado: (2021)

Verifying in vitro‐determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically‐based pharmacokinetic modeling
por: Yeung, Cindy H. T., et al.
Publicado: (2023)

The Future of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure in Pregnant Women
por: Vinks, A A
Publicado: (2013)

Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker
por: Zhang, Miao, et al.
Publicado: (2022)

Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
por: Jones, HM, et al.
Publicado: (2013)

Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results.
por: Spear, R C, et al.
Publicado: (1994)

Predicting the systemic exposure and lung concentration of nafamostat using physiologically-based pharmacokinetic modeling
por: Jeong, Hyeon-Cheol, et al.
Publicado: (2022)

Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry
por: Rowland, M
Publicado: (2013)

A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children
por: Sjögren, Erik, et al.
Publicado: (2021)

Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations
por: Shen, Chaozhuang, et al.
Publicado: (2023)

Epirubicin-induced Kounis syndrome
por: Liang, Hui-zhu, et al.
Publicado: (2021)

A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins
por: Gill, Katherine L., et al.
Publicado: (2015)

Comparison of operating room variables, radiation exposure and implant costs for WEB versus stent assisted coiling for treatment of wide neck bifurcation aneurysms
por: Rai, Ansaar T, et al.
Publicado: (2020)

Addressing drug safety of maternal therapy during breastfeeding using physiologically‐based pharmacokinetic modeling
por: Pan, Xian, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Acetaminophen Metabolism and Pharmacokinetics in Children
por: Jiang, X-L, et al.
Publicado: (2013)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects
por: Matsumoto, Yuki, et al.
Publicado: (2018)

Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically‐Based Pharmacokinetic Modeling
por: Yellepeddi, Venkata K., et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Interstrain Variability in Trichloroethylene Metabolism in the Mouse
por: Chiu, Weihsueh A., et al.
Publicado: (2014)

Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting Haloperidol Exposure in Healthy and Disease Populations
por: Alasmari, Mohammed S., et al.
Publicado: (2022)

Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making
por: Rowland, M, et al.
Publicado: (2015)

Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations
por: Johnson, Trevor N., et al.
Publicado: (2022)

Modeling Interindividual Variability in Physiologically Based Pharmacokinetics and Its Link to Mechanistic Covariate Modeling
por: Huisinga, W, et al.
Publicado: (2012)

Comparison of the Use of a Physiologically Based Pharmacokinetic Model and a Classical Pharmacokinetic Model for Dioxin Exposure Assessments
por: Emond, Claude, et al.
Publicado: (2005)

Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug–Drug Interactions Involving Modafinil
por: Rowland, Angela, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2sml5t25nsoj31pqigir3eg3v8